Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deciphering IL-1 Mediated Inflammation for Targeted Treatment of Dilated Cardiomyopathy
2024-514861-21-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dilated cardiomyopathy (DCM), inflammatory cardiomyopathy and heart failure (HF) comparing Anakinra plus standard of care with Standard of care alone (2 arms). Primary endpoint: Improvement in left-ventricular ejection fraction at 4 weeks. Planned start Oct 2024; status: authorised.
02
Drugs
anakinra
03
Conditions
dilated cardiomyopathy (DCM)inflammatory cardiomyopathyheart failure (HF)
Beyond the preview
Go deeper on 2024-514861-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514861-21-00.